GlassScriptPhysician profile
Roger H Tsai
NPI 1396783593
$2,494.78
in general payments reported to CMS, 2019-2025
17 companies · $635 in 2025
The $635 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $139 · 2021: $179 · 2022: $404 · 2023: $419 · 2024: $574 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $529.36 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $508.59 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $428.64 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $166.70 | 2022-2025 | Infuse, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.95 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $165.30 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $147.68 | 2022-2024 | |
| Alcon Vision LLC | $69.32 | 2025 | Eysuvis, Tryptyr |
| Coopervision INC. | $69.16 | 2021-2025 | Myday Contact Lens |
| Dompe US, INC. | $57.80 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $47.99 | 2021 | |
| Shire North American Group INC | $44.26 | 2019 | |
| Sight Sciences, INC. | $24.68 | 2025 | Tearcare System |
| Visioneering Technologies, INC. | $22.47 | 2019 | |
| Biotissue Holdings INC. | $16.22 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $15.61 | 2022 | |
| Thea Pharma INC. | $15.05 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.